METHYLPREDNISOLONE SODIUM SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Methylprednisolone Sodium Succinate patents expire, and when can generic versions of Methylprednisolone Sodium Succinate launch?
Methylprednisolone Sodium Succinate is a drug marketed by Abraxis Pharm, Amneal, Bedford Labs, Elkins Sinn, Eugia Pharma, Fresenius Kabi Usa, Hikma, Intl Medication, Sagent Pharms Inc, Teva Parenteral, Tianjin Kingyork, and Watson Labs. and is included in thirty-three NDAs.
The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methylprednisolone Sodium Succinate
A generic version of METHYLPREDNISOLONE SODIUM SUCCINATE was approved as methylprednisolone sodium succinate by FRESENIUS KABI USA on July 30th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHYLPREDNISOLONE SODIUM SUCCINATE?
- What are the global sales for METHYLPREDNISOLONE SODIUM SUCCINATE?
- What is Average Wholesale Price for METHYLPREDNISOLONE SODIUM SUCCINATE?
Summary for METHYLPREDNISOLONE SODIUM SUCCINATE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 33 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 39 |
| Clinical Trials: | 34 |
| Patent Applications: | 4,026 |
| DailyMed Link: | METHYLPREDNISOLONE SODIUM SUCCINATE at DailyMed |
Recent Clinical Trials for METHYLPREDNISOLONE SODIUM SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Maasstad Hospital | Phase 3 |
| Medisch Spectrum Twente | Phase 3 |
| HagaZiekenhuis | Phase 3 |
Pharmacology for METHYLPREDNISOLONE SODIUM SUCCINATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for METHYLPREDNISOLONE SODIUM SUCCINATE
US Patents and Regulatory Information for METHYLPREDNISOLONE SODIUM SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Parenteral | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 081266-001 | Nov 30, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Intl Medication | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 087812-001 | Feb 9, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 086953-001 | Jul 22, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tianjin Kingyork | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 212396-001 | Apr 20, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 087030-001 | Jul 22, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
